Back to top Open menu arrow
Purchase PDF Reprints

The Journal of
Clinical Psychiatry
Members only

The Journal of Clinical Psychiatry

Original Research Focus on Suicide September 21, 2026

The Role of Chronic Anhedonia in the Relationship Between Treatment-Resistant Depression and Suicidality

; ; ; ; ; ;

J Clin Psychiatry 2026;87(3):25m16189

Abstract

Objective: Treatment-resistant depression (TRD) is a severe form of major depressive disorder (MDD) associated with increased suicidality. Anhedonia, the reduced ability to experience pleasure, is recognized across various psychiatric conditions, including TRD. This study aims to investigate the relationship between chronic anhedonia, or low hedonic tone, and suicidal behavior in patients with TRD.

Methods: A cohort of 160 participants from the START Clinic for Mood and Anxiety Disorders in Toronto, Canada, was assessed. Diagnosis of TRD followed criteria established by McIntyre et al (2014) and used the Mini International Neuropsychiatric Interview (MINI) 6.0.0 diagnostic evaluation. Chronic anhedonia was classified using the MINI module A, and suicidality was assessed using the MINI Suicide Module.

Results: Of the 160 participants, 97 met the criteria for TRD. Within the TRD group, 58% reported chronic anhedonia. Participants with TRD and chronic anhedonia were 2.4-fold more likely to report suicidal ideation (P=.049) and 3.9-fold more likely to report a suicide attempt (P=.035) in the preceding month than those without chronic anhedonia.

Conclusion: Chronic anhedonia is significantly associated with an increased risk of suicidal ideation and attempts in patients with TRD. Clinicians should consider chronic anhedonia as a key risk factor for suicidality in this population and prioritize its assessment and management.

J Clin Psychiatry 2026;87(3):25m16189

Author affiliations are listed at the end of this article.

Also from JCP

The Regulatory Maze of Ketamine and Psychedelics with Benjamin Brody, MD Evaluation of Sexual Function With Adjunctive Lumateperone in Major Depressive Disorder Electroconvulsive Therapy and All-Cause, Nonsuicide, and Suicide Mortality

From the Editors

New Series The JCP Podcast Take-home ketamine for depression? Dr. Benjamin Brody calls the answer an unambiguous no, citing self-escalation risk, a narrow therapeutic index, and rare but terrifying dysphoric dissociation. He also unpacks why esketamine's tightly monitored REMS pathway looks nothing like the largely unregulated ketamine market.

Members Only Content

This full article is available exclusively to Professional tier members. Subscribe now to unlock the HTML version and gain unlimited access to our entire library plus all PDFs. If you're already a subscriber, please log in below to continue reading.

Subscribe Now

Already a member? Log in

  1. Murray CJL, Lopez AD. Evidence-based health policy—lessons from the Global Burden of Disease Study. Science. 1996;274(5288):740–743. PubMed CrossRef
  2. Ferrari AJ, Santomauro DF, Mantilla Herrera AM, et al. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137–150. PubMed
  3. Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). Pharmacoeconomics. 2021;39(6):653–665. PubMed CrossRef
  4. Chiu M, Lebenbaum M, Cheng J, et al. The direct healthcare costs associated with psychological distress and major depression: a population-based cohort study in Ontario, Canada. PLoS One. 2017;12(9):e0184268. PubMed CrossRef
  5. Tanner JA, Hensel J, Davies PE, et al. Economic burden of depression and associated resource use in Manitoba, Canada. Can J Psychiatry. 2020;65(5):338–346. PubMed CrossRef
  6. Shields M, Tonmyr L, Gonzalez A, et al. Symptoms of major depressive disorder during the COVID-19 pandemic: results from a representative sample of the Canadian population. Health Promot Chronic Dis Prev Can. 2021;41(11):340–358. PubMed CrossRef
  7. McKnight PE, Kashdan TB. The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev. 2009;29(3):243–259. PubMed CrossRef
  8. Üstün B, Kennedy C. What is “functional impairment”? Disentangling disability from clinical significance. World Psychiatry. 2009;8(2):82–85. PubMed CrossRef
  9. Bachmann S. Epidemiology of suicide and the psychiatric perspective. Int J Environ Res Public Health. 2018;15(7):1425. PubMed CrossRef
  10. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649–659. PubMed CrossRef
  11. Amos TB, Tandon N, Lefebvre P, et al. Direct and indirect cost burden and change of employment status in treatment-resistant depression. J Clin Psychiatry. 2018;79(2):24–32. CrossRef
  12. McCrone P, Rost F, Koeser L, et al. The economic cost of treatment-resistant depression in patients referred to a specialist service. J Ment Health. 2018;27(6):567–573. PubMed CrossRef
  13. Olchanski N, McInnis Myers M, Halseth M, et al. The economic burden of treatment-resistant depression. Clin Ther. 2013;35(4):512–522. PubMed CrossRef
  14. Liu Y, Zhang J, Sun L. Who are likely to attempt suicide again? A comparative study between the first and multiple timers. Compr Psychiatry. 2017;78:54–60. PubMed CrossRef
  15. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. Br J Psychiatry. 1997;170(3):205–228. PubMed CrossRef
  16. Kessler RC, Bossarte RM, Luedtke A, et al. Suicide prediction models: a critical review of recent research with recommendations for the way forward. Mol Psychiatry. 2020;25(1):168–179. PubMed CrossRef
  17. Schwartz-Lifshitz M, Zalsman G, Giner L, et al. Can we really prevent suicide?. Curr Psychiatry Rep. 2012;14(6):624–633. PubMed CrossRef
  18. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119–142. PubMed CrossRef
  19. Hankey J, MEd M, Liu Y, et al. Adult ADHD: prevalence, comorbidities, and patient-reported dysfunction in a tertiary mental health Clinic. Psychiatry Clin Psychopharmacol. 2020(0):1. CrossRef
  20. Thomsen KR. Measuring anhedonia: impaired ability to pursue, experience, and learn about reward. Front Psychol. 2015;6:1409. PubMed CrossRef
  21. Bonanni L, Gualtieri F, Lester D, et al. Can anhedonia be considered a suicide risk factor? A review of the literature. Med (B Aires). 2019;55(8):458. PubMed CrossRef
  22. Gillissie ES, Le GH, Rhee TG, et al. Evaluating anhedonia as a risk factor in suicidality: a meta-analysis. J Psychiatr Res. 2023;158:209–215. PubMed CrossRef
  23. Ballard ED, Wills K, Lally N, et al. Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. J Affect Disord. 2017;218:195–200. PubMed CrossRef
  24. McIntyre RS, Filteau MJ, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1–7. PubMed CrossRef
  25. Sheehan D, Lecrubier Y, Harnett Sheehan K, et al. The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry. 1997;12(5):232–241. CrossRef
  26. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20:22-33):22–57. quiz 34-57. PubMed
  27. Lecrubier Y, Sheehan D, Weiller E, et al. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry. 1997;12(5):224–231. CrossRef
  28. Haavik J, Halmøy A, Lundervold AJ, et al. Clinical assessment and diagnosis of adults with attention-deficit/hyperactivity disorder. Expert Rev Neurother. 2010;10(10):1569–1580. PubMed CrossRef
  29. Sternat T, Fotinos K, Fine A, et al. Low hedonic tone and attention-deficit hyperactivity disorder: risk factors for treatment resistance in depressed adults. Neuropsychiatr Dis Treat. 2018;14:2379–2387. PubMed CrossRef
  30. Amorim P. Mini International Neuropsychiatric Interview (MINI): validação de entrevista breve para diagnóstico de transtornos mentais. Rev Bras Psiquiatr. 2000;22(3):106–115. CrossRef
  31. Sternat T, Katzman M. Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse. Neuropsychiatr Dis Treat. 2016;12:2149–2164. PubMed CrossRef
  32. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association; 2013.
  33. Kouros CD, Morris MC, Garber J. Within-person changes in individual symptoms of depression predict subsequent depressive episodes in adolescents: a prospective Study. J Abnorm Child Psychol. 2016;44(3):483–494. PubMed CrossRef
  34. Wilcox HC, Anthony JC. Child and adolescent clinical features as forerunners of adult-onset major depressive disorder: retrospective evidence from an epidemiological sample. J Affect Disord. 2004;82(1):9–20. PubMed CrossRef
  35. Sheehan DV, Giddens JM, Sheehan IS. Status update on the Sheehan-Suicidality Tracking Scale (S-STS) 2014. Innov Clin Neurosci. 2014;11(9-10):93–140. PubMed
  36. Sternat T, Fotinos K, Fine A, et al. ADHD and chronic anhedonia as predictors of treatment response and suicidality in individuals with generalized anxiety disorder. Presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting; May 29–June 1, 2018; Miami, Florida.
  37. Snaith RP, Hamilton M, Morley S, et al. A scale for the assessment of hedonic tone: the Snaith–Hamilton Pleasure Scale. Br J Psychiatry. 1995;167(1):99–103. PubMed CrossRef
  38. Knutson B, Westdorp A, Kaiser E, et al. FMRI visualization of brain activity during a monetary incentive delay task. Neuroimage. 2000;12(1):20–27. PubMed CrossRef

About the Authors

Buy PDF for $40

Please sign in or purchase this PDF for $40.

The Journal of Clinical Psychiatry June 2026 cover with featured article titles

Vol 87 • 2026 • Number 2

Read the Current Issue

Original Research

CBT following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial

Original Research

Neuropsychiatric Symptom Clusters and Brain Structure in Alzheimer’s Disease

Systematic Review

Thirty Years of the Diagnostic Criteria for Psychosomatic Research

Original Research

Efficacy of Olanzapine/Samidorphan on Negative Symptoms

Original Research

Comparing Risk Prediction for Suicide Attempts and Deaths After Emergency Department Visits

Clinical and Practical Psychopharmacology

Insomnia, Sleep, and the Use of Sedative-Hypnotic Drugs: Practical Notes
View current Issue

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe